|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.90 CHF | +0.19% |
|
-0.38% | -5.30% |
| Feb. 25 | Basilea Pharmaceutica Secures Additional $6 Million Funding for Antibiotic Development | MT |
| Feb. 25 | Basilea receives USD 6 mln from BARDA for antibiotic ceftibuten-ledaborbactam development | RE |
| Capitalization | 637M 806M 705M 609M 1.11B 74.57B 1.15B 7.61B 3.01B 35.63B 3.03B 2.96B 129B | P/E ratio 2026 * |
13.9x | P/E ratio 2027 * | 15.6x |
|---|---|---|---|---|---|
| Enterprise value | 504M 638M 558M 482M 877M 59B 911M 6.02B 2.38B 28.19B 2.39B 2.34B 102B | EV / Sales 2026 * |
2x | EV / Sales 2027 * | 1.76x |
| Free-Float |
91.97% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | +0.19% | ||
| 1 week | -0.38% | ||
| Current month | -6.16% | ||
| 1 month | -9.12% | ||
| 3 months | -4.43% | ||
| 6 months | +13.97% | ||
| Current year | -5.30% |
| 1 week | 51.4 |  | 54.4 |
| 1 month | 50.6 | | 56 |
| Current year | 50.6 | | 59.2 |
| 1 year | 37.5 | | 59.7 |
| 3 years | 32 | | 59.7 |
| 5 years | 29.55 | | 59.7 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 2018-04-18 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 2019-04-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 2011-11-28 |
| Chairman | 71 | 2013-04-08 | |
Nicole Onetto
BRD | Director/Board Member | 72 | 2017-04-26 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.19% | -0.38% | +9.40% | +4.23% | 806M | |
| +0.17% | -4.60% | -12.29% | -7.25% | 42.78B | |
| -0.44% | -5.67% | +9.59% | +20.39% | 31.5B | |
| -0.24% | -3.29% | +14.84% | +48.42% | 29.99B | |
| +1.10% | -5.60% | -11.05% | -15.65% | 27.65B | |
| -0.22% | -3.60% | +142.48% | +312.79% | 18.8B | |
| -1.32% | -6.10% | +47.72% | +108.24% | 13.87B | |
| +1.48% | -4.29% | +38.61% | +153.12% | 12.78B | |
| -0.02% | -3.24% | +22.53% | -0.36% | 12.39B | |
| -1.59% | -3.85% | +115.99% | +108.22% | 11.76B | |
| Average | -0.09% | -3.81% | +37.78% | +73.22% | 20.23B | |
| Weighted average by Cap. | -0.03% | -4.05% | +26.69% | +59.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 252M 320M 279M 242M 439M 29.57B 457M 3.02B 1.2B 14.13B 1.2B 1.17B 51.02B | 267M 338M 296M 255M 465M 31.28B 483M 3.19B 1.26B 14.95B 1.27B 1.24B 53.98B |
| Net income | 36.1M 45.71M 39.96M 34.53M 62.81M 4.23B 65.29M 431M 171M 2.02B 172M 168M 7.3B | 83.44M 106M 92.35M 79.82M 145M 9.77B 151M 997M 395M 4.67B 396M 388M 16.86B |
| Net Debt | -133M -168M -147M -127M -231M -15.57B -240M -1.59B -629M -7.44B -632M -618M -26.87B | -165M -209M -183M -158M -288M -19.36B -299M -1.98B -783M -9.25B -786M -769M -33.41B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-13 | 51.80 CHF | -1.52% | 29,051 |
| 26-03-12 | 52.60 CHF | -0.38% | 24,395 |
| 26-03-11 | 52.80 CHF | -2.22% | 26,091 |
| 26-03-10 | 54.00 CHF | +2.27% | 24,415 |
| 26-03-09 | 52.80 CHF | +1.54% | 38,464 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
